Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer

NCT01282333 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

44

Enrollment

NIH

Sponsor class

Conditions

Advanced Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
Stage III Bladder Cancer
Stage III Pancreatic Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Bladder Cancer
Stage IV Non-small Cell Lung Cancer
Stage IV Pancreatic Cancer
Transitional Cell Carcinoma of the Bladder
Unresectable Extrahepatic Bile Duct Cancer
Unresectable Gallbladder Cancer

Interventions

DRUG: gemcitabine hydrochloride
DRUG: veliparib
OTHER: diagnostic laboratory biomarker analysis
OTHER: pharmacological study
DRUG: cisplatin

Sponsor

National Cancer Institute (NCI)